Assembling evidence grade
Loading
Independent evidence before payment.
Melanocortin receptor agonist · also: Bremelanotide, Vyleesi
PT-141 carries an Evidence Grade of A (High confidence). The strongest published evidence catalogued is human rct / review.
Grade A rule: Two or more confirmatory human RCTs (an approved product, or completed Phase 3).
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
PT-141 (bremelanotide) is a melanocortin agonist with randomised human evidence; a branded formulation is approved for a specific indication.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 3 randomised human trials here — the strongest kind of evidence. That is about the research, not about any particular seller or batch.
Strongest: randomised or pooled human trials.
Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options. Journal of minimally invasive gynecology, 2026.
Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022.
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. The Annals of pharmacotherapy, 2020.
Observational, open-label or small human studies.
none catalogued
Preclinical animal models — not a human outcome.
none catalogued
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Bremelanotide. PubMed, 2025.
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023.
Targeting the central melanocortin system for the treatment of metabolic disorders. Nature reviews. Endocrinology, 2023.
Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international, 2022.
Bremelanotide. PubMed, 2021.
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. Journal of midwifery & women's health, 2021.
Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. The Medical letter on drugs and therapeutics, 2019.
Bremelanotide: First Approval. Drugs, 2019.
PT-141 Palatin. Current opinion in investigational drugs (London, England : 2000), 2004.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Approved evidence is indication-specific and concerns a branded product, not unbranded research material.
An approved prescription-only medicine. Buying it without a prescription bypasses medical supervision and the approved supply chain — a vendor selling it as “research use only” is offering a prescription drug with no prescription and no clinical oversight.
PepCred flags any vendor selling this compound without requiring a prescription as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Sample of 8 (not ranked) — see all on ClinicalTrials.gov:
The molecule is FDA-approved (US) as a branded medicine (Vyleesi). The unbranded, research-grade material sold as PT-141 is a different, unapproved product of unverified identity, purity and concentration.
Reporting volume (not a safety rate): 1,004 adverse-event reports name this ingredient in the FDA FAERS database. FAERS reports are voluntary and unverified, are not a rate, and do not establish that the drug caused the event — high counts usually track high prescribing volume.
PepCred note: Approved branded formulation for a specific indication (FDA).
PT-141 is a prescription-only medicine. The lawful route is a prescriber and a GPhC-registered pharmacy — never a grey-market seller.
Get PT-141 only through a prescriber and a GPhC-registered pharmacy. The registered pharmacies in the PepCred directory are UK weight-management (GLP-1) services and may not dispense PT-141 — ask a pharmacy or your GP, and check any pharmacy against the official register before you buy.
An ingredient-name listing is not the licensed branded medicine. These unranked records are shown to expose prescription bypass and other risks, not to suggest where to buy.
None of these is verified for human use.